Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: -2.4%
1M: -6.8%
3M: -14.9%
YTD: +17.0%
1Y: -20.6%
3Y: +29.6%
5Y: -33.1%
$31.80
-0.68 (-2.09%)
Weekly Expected Move ±4.6%
$29
$30
$32
$33
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
AXQ Capital LP Acquires Shares of 27,656 Agios Pharmaceuticals, Inc. $AGIO
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Agios gains FDA priority review for Pyrukynd label expansion
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios (AGIO) Q1 2026 Earnings Call Transcript
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Earnings Scheduled For April 29, 2026
Agios Pharmaceuticals GAAP EPS of -$1.69 beats by $0.11, revenue of $20.75M beats by $7.41M
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Here are the major earnings before the open Wednesday
Agios Pharmaceuticals Q1 2026 Earnings Preview
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
Agios (AGIO) Q3 2024 Earnings Call Transcript
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
Agios (AGIO) Q2 2025 Earnings Call Transcript
Agios (AGIO) Q3 2025 Earnings Transcript
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
12 Health Care Stocks Moving In Monday's Intraday Session
Here's Why Agios Pharmaceuticals Crashed 23% Today
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
Why Agios Pharmaceuticals Stock Is Dropping Again - TipRanks
(AGIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
A Look At Agios Pharmaceuticals (AGIO) Valuation As PYRUKYND Growth Prospects Face Mixed Signals - simplywall.st
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036
SG Americas Securities LLC Increases Position in Agios Pharmaceuticals, Inc. $AGIO
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Agios (AGIO) CCO vests 8,500 PSUs, sells 3,262 shares for taxes - Stock Titan
Agios will webcast first-quarter results before markets open April 29 - Stock Titan
Agios (NASDAQ: AGIO) CFO exercises PSUs, automatic share sale for taxes - Stock Titan
Agios (NASDAQ: AGIO) CLO exercises 8,500 PSUs and sells shares for taxes - Stock Titan
Agios (NASDAQ: AGIO) exec sells shares to cover PSU tax obligations - Stock Titan
AGIO SEC Filings - Agios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - Yahoo Finance
Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher
The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily
Sector Update: Health Care Stocks Higher Late Afternoon
Sector Update: Health Care Stocks Higher Tuesday Afternoon
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.
$AGIO stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - The Motley Fool
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything - The Motley Fool
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - PR Newswire
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
ArrowMark Colorado Holdings LLC Has $27.29 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO
Servier’s $2.5B cancer bet underlines a quick oncology growth strategy
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets